Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients

American Journal of Kidney Diseases

Volumn 67, Issue 1, 2016, Pages 119-127

  Brookhart, M Alan ^a,b   Freburger, Janet K ^b   Ellis, Alan R ^b   Winkelmayer, Wolfgang C ^c   Wang, Lily ^b   Kshirsagar, Abhijit V ^d  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; cardiovascular events; chronic kidney disease (CKD); end stage renal disease (ESRD); hemodialysis (HD); hospitalization; infection; intravenous iron formulations; iron sucrose; mortality; safety; sodium ferric gluconate

Indexed keywords

FERRIC GLUCONATE; IRON SACCHARATE; ANTIANEMIC AGENT; FERRIC ION; FERRIC OXIDE, SACCHARATED; SACCHARIC ACID;

ADULT; ANEMIA; ARTICLE; ATTRIBUTABLE RISK; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIALYSIS CATHETER; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFECTION RELATED HOSPITALIZATION; INFECTION RELATED MORTALITY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; RETROSPECTIVE STUDY; ANEMIA, IRON-DEFICIENCY; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TIME FACTOR;

ANEMIA, IRON-DEFICIENCY; COHORT STUDIES; FEMALE; FERRIC COMPOUNDS; GLUCARIC ACID; HEMATINICS; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84955210746     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.07.026     Document Type: Article

References (31)

1. US Renal Data System USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2009 US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
2. A.J. Collins, S. Li, W. St Peter, and et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39% J Am Soc Nephrol 12 11 2001 2465 2473
3. S. Fishbane, and J.K. Maesaka Iron management in end-stage renal disease Am J Kidney Dis 29 3 1997 319 333
4. A. Besarab, and D.W. Coyne Iron supplementation to treat anemia in patients with chronic kidney disease Nat Rev Nephrol 6 12 2010 699 710
5. G. Faich, and J. Strobos Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans Am J Kidney Dis 33 3 1999 464 470
6. R. Fletes, J.M. Lazarus, J. Gage, and G.M. Chertow Suspected iron dextran-related adverse drug events in hemodialysis patients Am J Kidney Dis 37 4 2001 743 749
7. B.G. Danielson Structure, chemistry, and pharmacokinetics of intravenous iron agents J Am Soc Nephrol 15 suppl 2 2004 S93 S98
8. G.R. Aronoff Safety of intravenous iron in clinical practice: implications for anemia management protocols J Am Soc Nephrol 15 suppl 2 2004 S99 S106
9. U.C. Brewster Intravenous iron therapy in end-stage renal disease Semin Dial 19 4 2006 285 290
10. A.V. Kshirsagar, J. Freburger, A. Ellis, L. Wang, W. Winkelmayer, and M.A. Brookhart The comparative short-term effectiveness of iron dosing and formulations in us hemodialysis patients Am J Med 126 6 2012 541.e1 541.e14
11. E. Coppol, J. Shelly, S. Cheng, Y. Kaakeh, and B. Shepler A comparative look at the safety profiles of intravenous iron products used in the hemodialysis population (February) Ann Pharmacother 45 2 2011 241 247
12. US Renal Data System. Researcher's Guide to the USRDS Database: 2010 ADR Edition. http://www.usrds.org/2010/rg/A-intro-sec-1-10.pdf. Accessed September 11, 2015.
13. A. Elixhauser, C. Steiner, D.R. Harris, and R.M. Coffey Comorbidity measures for use with administrative data Med Care 36 1 1998 8 27
14. S.N. Wood Thin plate regression splines J R Stat Soc B 65 1 2003 95 114
15. M.A. Brookhart, J.K. Freburger, A.R. Ellis, L. Wang, W.C. Winkelmayer, and A.V. Kshirsagar Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients J Am Soc Nephrol 24 7 2013 1151 1158
16. R: A Language and Environment for Statistical Computing [computer program] 2014 R Foundation for Statistical Computing Vienna, Austria
17. D. Westreich, and S.R. Cole Invited commentary: positivity in practice Am J Epidemiol 171 6 2010 674 677 discussion 678-681
18. A.V. Kshirsagar, J.K. Freburger, A.R. Ellis, L. Wang, W.C. Winkelmayer, and M.A. Brookhart Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients PLoS One 8 11 2013 e78930
19. A. Besarab, S. Frinak, and J. Yee An indistinct balance: the safety and efficacy of parenteral iron therapy J Am Soc Nephrol 10 9 1999 2029 2043
20. E. Cieri Does iron cause bacterial infections in patients with end stage renal disease? ANNA J 26 6 1999 591 596
21. S. Fishbane Review of issues relating to iron and infection Am J Kidney Dis 34 4 suppl 2 1999 S47 S52
22. B. Hoen Iron and infection: clinical experience Am J Kidney Dis 34 4 suppl 2 1999 S30 S34
23. S.I. Patruta, and W.H. Horl Iron and infection Kidney Int Suppl 69 1999 S125 S130
24. R.L. Jurado Iron, infections, and anemia of inflammation Clin Infect Dis 25 4 1997 888 895
25. L. Maynor, and D.F. Brophy Risk of infection with intravenous iron therapy Ann Pharmacother 41 9 2007 1476 1480
26. R.A. Zager, A.C. Johnson, and S.Y. Hanson Parenteral iron therapy exacerbates experimental sepsis Kidney Int 65 6 2004 2108 2112
27. A.J. Collins, J. Ebben, J.Z. Ma, and H. Xia Iron dosing patterns and mortality [abstract] J Am Soc Nephrol 9 1998 250A
28. G. Sirken, R. Raja, and A.R. Rizkala Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients Clin Nephrol 66 5 2006 348 356
29. M.P. Kooistra, S. Kersting, I. Gosriwatana, and et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion Eur J Clin Invest 32 suppl 1 2002 36 41
30. T.M. Rooyakkers, E.S. Stroes, M.P. Kooistra, and et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo Eur J Clin Invest 32 suppl 1 2002 9 16
31. J. Parkkinen, L. von Bonsdorff, S. Peltonen, C. Gronhagen-Riska, and K. Rosenlof Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration Nephrol Dial Transplant 15 11 2000 1827 1834